Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Trial ID or NCT#

NCT05564377

Status

recruiting iconRECRUITING

Purpose

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Official Title

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

James Ford
James Ford
Medical oncologist, Gastrointestinal specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics

Contact us to find out if this trial is right for you.

Contact

Feriel Buchholz
650-721-4090